Clinical Trials Browser

Phase 2 × Adenocarcinoma of the Prostate × pazopanib × Clear all

NCT01832259 2018-12-12

A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection

Phase 2 Completed

30 enrolled 10 charts

Adenocarcinoma of the Prostate